Involvement of MAF1 homolog, negative regulator of RNA polymerase III in colorectal cancer progression

Hokonohara,Kentaro; Nishida,Naohiro; Miyoshi,Norikatsu; Takahashi,Hidekazu; Haraguchi,Naotsugu; Hata,Taishi; Matsuda,Chu; Mizushima,Tsunekazu; Doki,Yuichiro; Mori,Masaki

doi:10.3892/ijo.2019.4678

Involvement of MAF1 homolog, negative regulator of RNA polymerase III in colorectal cancer progression

Authors:
- Kentaro Hokonohara
- Naohiro Nishida
- Norikatsu Miyoshi
- Hidekazu Takahashi
- Naotsugu Haraguchi
- Taishi Hata
- Chu Matsuda
- Tsunekazu Mizushima
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan
Published online on: January 7, 2019 https://doi.org/10.3892/ijo.2019.4678
Pages: 1001-1009
Copyright: © Hokonohara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polymerase (Pol) III‑dependent transcription controls the abundance of transfer RNAs, 5S ribosomal RNA and small non‑coding RNAs within cells, and is known to serve an essential role in the maintenance of intracellular homeostasis. However, its contribution to cancer progression has not been extensively explored. The present study demonstrated that the evolutionarily conserved MAF1 homolog, negative regulator of RNA Pol III (MAF1) may be closely associated with malignant potential and poor prognosis in colorectal cancer (CRC). Notably, immunohistochemical analysis of 146 CRC surgical specimens revealed that high expression levels of MAF1 were associated with advanced tumor depth, lymph node metastasis, distant metastasis and poor prognosis. In vitro loss‑of‑function assays revealed that MAF1 knockdown suppressed chemoresistance and migration of CRC cancer cells. Furthermore, detailed analysis of an independent CRC dataset (n=615) demonstrated that the prognostic impact of MAF1 gene expression was particularly marked in microsatellite instability (MSI)‑positive patients, who benefit from immune checkpoint blockade. High expression levels of MAF1 were revealed to be an independent prognostic indicator in MSI‑positive CRC. These findings suggested that MAF1 may have an essential role in CRC progression, particularly in MSI‑positive cases.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM and Forman D: Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y and Mori M: Gastroenterological surgery in Japan: The past, the present and the future. Ann Gastroenterol Surg. 1:5–10. 2017. View Article : Google Scholar : PubMed/NCBI
3	Pradhan A, Hammerquist AM, Khanna A and Curran SP: The C box rgion of MAF1 regulates transcriptional activity and protein stability. J Mol Biol. 429:192–207. 2017. View Article : Google Scholar
4	Vannini A and Cramer P: Conservation between the RNA poly merase I, II, and III transcription initiation machineries. Mol Cell. 45:439–446. 2012. View Article : Google Scholar : PubMed/NCBI
5	White RJ: RNA polymerases I and III, non coding RNAs and cancer. Trends Genet. 24:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
6	Khanna A, Pradhan A and Curran SP: Emerging roles for MAF1 beyond the regulation of RNA polymerase III activity HHS Public Access. J Mol Biol. 427:2577–2585. 2015. View Article : Google Scholar : PubMed/NCBI
7	Johnson SS, Zhang C, Fromm J, Willis IM and Johnson DL: Mammalian Maf1 is a negative regulator of transcription by all three nuclear RNA polymerases. Mol Cell. 26:3673792007. View Article : Google Scholar : PubMed/NCBI
8	Palian BM, Rohira AD, Johnson SAS, He L, Zheng N, Dubeau L, Stiles BL and Johnson DL: Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism. PLoS Genet. 10:e10047892014. View Article : Google Scholar : PubMed/NCBI
9	Khanna A, Pradhan A and Curran SP: Emerging roles for Maf1 beyond the regulation of RNA polymerase III activity. J Mol Biol. 427:2577–2585. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li Y, Tsang CK, Wang S, Li XX, Yang Y, Fu L, Huang W, Li M, Wang HY and Zheng XF: MAF1 suppresses AKT mTOR signaling and liver cancer through activation of PTEN tran scription. Hepatology. 63:1928–1942. 2016. View Article : Google Scholar : PubMed/NCBI
11	Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al: Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29. 2012. View Article : Google Scholar
12	Sugimura K, Fujiwara Y, Omori T, Motoori M, Miyoshi N, Akita H, Gotoh K, Kobayashi S, Takahashi H, Noura S, et al: Clinical importance of a transcription reverse transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre and post lymphadenectomy from gastric cancer patients. Surg Today. 46:654–660. 2016. View Article : Google Scholar
13	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
14	Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
15	Graczyk D, White RJ and Ryan KM: Involvement of RNA poly merase III in immune responses. Mol Cell Biol. 35:1848–1859. 2015. View Article : Google Scholar : PubMed/NCBI
16	Chiu YH, Macmillan JB and Chen ZJ: RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG I pathway. Cell. 138:576–591. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, et al: Effects of microsatellite insta bility on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 115:25–33. 2016. View Article : Google Scholar : PubMed/NCBI
18	Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD 1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
19	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
20	Giancotti FG: Mechanisms governing metastatic dormancy and reactivation. Cell. 155:750–764. 2013. View Article : Google Scholar : PubMed/NCBI
21	Senft D and Ronai ZA: Adaptive stress responses during tumor metastasis and dormancy. Trends Cancer. 2:429–442. 2016. View Article : Google Scholar : PubMed/NCBI
22	McLean KJ and Jacobs Lorena M: Plasmodium falciparum Maf1 confers survival upon amino acid starvation. MBio. 8:e02317 e162017. View Article : Google Scholar
23	Orioli A, Praz V, Lhôte P and Hernandez N: Human MAF1 targets and represses active RNA polymerase III genes by preventing recruitment rather than inducing long term transcriptional arrest. Genome Res. 26:624–635. 2016. View Article : Google Scholar : PubMed/NCBI
24	Whiteside TL: Immune responses to cancer: Are they potential biomarkers of prognosis? Front Oncol. 3:1072013. View Article : Google Scholar : PubMed/NCBI
25	Galon J, Costes A, Sanchez Cabo F, Kirilovsky A, Mlecnik B, Lagorce Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predictclinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
26	Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al: The consensus molecular subtypes of colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent Puig P, Gryfe R, Shepherd LE, et al: Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemo therapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
28	Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006. View Article : Google Scholar : PubMed/NCBI
29	ZhangBWangJWangXZhuJLiuQShiZChambersMCZimmermanLJShaddoxKFKimSet al NCI CPTAC: Proteogenomic characterization of human colon and rectal cancer. Nature. 513:382–387. 2014. View Article : Google Scholar : PubMed/NCBI
30	Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al: Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22:679–684. 2016. View Article : Google Scholar : PubMed/NCBI